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COST-EFFECTIVENESS OF ROUX-EN-Y GASTRIC BYPASS IN TYPE 2 
DIABETES PATIONTS IN CANADA
Hashemi L, Minshall ME
Covidien, North Haven, CT, USA
OBJECTIVES: Our objective was to estimate the cost-effectiveness of Roux-en-Y 
Gastric Bypass (RYGB) for treating obese patients with type 2 diabetes mellitus 
(T2DM) in Canada compared with standard medical management using clinical data 
from a prospective observational study conducted at an academic medical center in 
the United States. METHODS: Our study used the CORE Diabetes Model which 
employs Monte Carlo simulation with tracker variables to estimate the lifetime costs 
and clinical outcomes of RYGB as a treatment for obese patients with T2DM com-
pared with standard medical management. Costs ($CAN 2009) and clinical outcomes 
were discounted at 5% consistent with Canadian-speciﬁc guidelines. RESULTS: The 
base-case analysis showed that RYGB improved life-expectancy and quality-adjusted 
life years (QALYs) compared with medical management of obese patients with T2DM 
at a lower cost and was therefore cost-saving in the base case. The incremental mean 
discounted life expectancy for RYGB was increased by 0.44 years while QALYs 
increased by 0.54 years. We doubled the price of RYGB in Canada (from $CAN 6,837 
to $CAN 13,674) while holding everything else constant and found that RYGB moved 
to an incremental cost-effectiveness ratio of $CAN 7,946 placing it well below the 
threshold value proposed by Laupacis et al in 1992 of $CAN 20,000 for a cost-
effective intervention worth adopting. CONCLUSIONS: The results of our study 
suggest that RYGB is cost saving in Canada compared with standard medical manage-
ment of obese patients with T2DM. Our results were robust to doubling the price of 
RYGB compared with medical management of T2DM in Canada.
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THE ECONOMIC IMPACT OF WEIGHT LOSS FOR PATIENTS WITH 
NEWLY DIAGNOSED TYPE 2 DIABETES MELLITUS (T2DM) IN THE US
Willis M1, Asseburg C2, Neslusan C3, He J3, Ingham M3
1IHE, Lund, Sweden, 2ESiOR, Kuopio, Finland, 3Johnson and Johnson Pharmaceutical Services 
L.L.C., Raritan, NJ, USA
OBJECTIVES: As excess weight adversely affects health outcomes in patients with 
T2DM, weight loss a fundamental goal of treatment. This study assessed the effect of 
weight reduction on long-term health outcomes and associated direct medical care 
costs for patients newly diagnosed with T2DM. METHODS: We simulated 500 
cohorts of 1000 patients over 25 years using the Economic and Health Outcomes 
(ECHO)-T2DM model, which captures the development of key micro- and macrovas-
cular diabetic complications. All patients were assumed to increase weight over time 
(0.51 pounds per year), however, half of the patients were assumed to lose 10 pounds 
in the ﬁrst year, so that a 10 pound differential was maintained. Pharmacotherapy 
was administered according to the 2009 American Diabetes Association Consensus 
Statement. The effect of weight on T2DM complications was modeled using risk 
equations from the UK Prospective Diabetes Study, wherein weight is a direct deter-
minant of the risk only of congestive heart failure (CHF). The risks of stroke and 
myocardial infarction are affected only indirectly via the linkage with CHF and mor-
tality risk is only affected indirectly via macrovascular event history. We assumed that 
weight change directly affects QALYs, utilizing T2DM-speciﬁc utility parameters from 
the CODE-2 study. Costs and health outcomes were discounted at 3%. RESULTS: 
Ten pounds of weight loss resulted in cost-savings of $613 over an average of 14.6 
years, mainly attributable to reductions in CHF incidence. Life years increased margin-
ally; QALYs, however, increased more substantially (0.16). CONCLUSIONS: At a 
willingness-to-pay threshold of $50,000, an intervention would be welfare improving 
at an incremental cost of up to $8,613 over 14.6 years. As this modeling exercise 
conservatively excluded a number of beneﬁts of weight loss (e.g., effects via improved 
lipids and blood pressure and reductions in cancer and other obesity-related illnesses), 
the true economic value is likely greater.
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MODELLING COST EFFECTIVENESS OF BEHAVIOUR MODIFICATION 
PROGRAMMES AND EFFECTS ON MEDICATION: CASE STUDY OF 
EDUCATION PROGRAMMES IN DIABETES
Brennan A, Gillett M
University of Shefﬁeld, SHEFFIELD, UK
OBJECTIVES: 1) To model long-term clinical and cost-effectiveness of the Diabetes 
Education and Self-Management for Ongoing and Newly Diagnosed (DESMOND) 
for people with newly diagnosed Type 2 diabetes, versus usual care in the UK; 2) To 
consider issues arising in modelling education / behaviour modiﬁcation programmes 
and how such modelling can support the development of clinical research. METHODS: 
The modelling undertakes a long-term cost-utility analysis with evidence from a 
12-month multicentre cluster RCT using the Shefﬁeld Type 2 Diabetes Model. Short 
and long-term outcomes include Hba1c, lipids and systolic blood pressure, patients’ 
weight and smoking status. The model examines long-term use of therapies including 
oral hypoglycemic agents. Risk / disease progression models based on UKPDS and 
other evidence are used to estimate incidence of complications, mortality, costs and 
health-related quality of life. RESULTS: Estimated mean (95% CI) incremental life-
time costs per person (trial based) = ≤ 218 (-≤ 194 to ≤ 758), incremental QALYs = 
0.0406 (-0.0283 to 0.1050), and incremental cost/QALY = ≤ 5369. Using current 
real-world costs, the incremental cost = ≤ 91 (-≤ 321 to ≤ 631) and incremental cost/
QALY = ≤2241. Probabilistic sensitivity analysis suggests an 87% likelihood of being 
cost effective at a ≤20,000/QALY threshold. One-way sensitivity analysis showed 
results are most affected by effects around weight and smoking, and that DESMOND 
would likely be cost effective under the conservative assumption of zero effect main-
tained after year one. CONCLUSIONS: Whilst results suggest that DESMOND is cost 
effective compared to usual care, further modelling should include: whether mainte-
nance of effect via longer-term top-up education is effective, subgroup analysis of those 
who respond / do not respond, direct modelling of exercise beneﬁts, and adaptation 
to education programmes such as Dose Adjustment for Normal Eating (DAFNE) in 
Type 1 diabetes.
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COST AND EFFECTIVENESS OF EDUCATIONAL STRATEGIES FOR THE 
CONTROL AND TREATMENT OF TYPE 2 DIABETES (DMT2) AND 
CARDIOVASCULAR RISK FACTORS (CVRF)
Caporale JE, Pﬁrter G, Elgart J, Gonzalez L, Rucci E, Lapertosa S, Villagra M, 
Gagliardino JJ
National University of La Plata, La Plata, Buenos Aires, Argentina
OBJECTIVES: To estimate and compare costs and effectiveness of different educa-
tional interventions at PRODIACOR study. METHODS: PRODIACOR is a prospec-
tive study (three years), randomized controlled trial, which aims to improve the quality 
of care for people with type 2 diabetes, optimizing the use of resources and prevent 
complications, thus reducing morbidity and socioeconomic cost. Includes 4 groups 
(control, educated patients, doctors educated and educated patients and physicians) 
of 9 physicians and 117 patients each. Clinical and metabolic changes were recorded 
in an ad-hoc form (annually and semiannually). Costs and utilization rates for drugs, 
consultations and practices were obtained from the administrative dataset of the cover-
age institutions involved. The intervention was approved by independent ethics com-
mittee. We performed a descriptive and inferential statistical analysis, verifying 
differences in means and proportions using t test, ANOVA and Chi square. RESULTS: 
Clinical and metabolic: although there was improvement of several registered indica-
tors no signiﬁcant differences in the percentage of patients at goal between groups 
were found. Cost: in the period before the intervention the total average expenditure 
for each patient was AR$ 1,848 (66% drugs, 26% practices and 8% consultations). 
No signiﬁcant differences between all the intervention groups were found. After the 
ﬁrst year all groups signiﬁcantly increased total average expenditure (Group 1: 259%; 
Group 2: 39%, Group 3: 59%, Group 4: 61%). The costs then progressively decreased 
in all groups and at the third year the total average expenditure was AR $1551 (72% 
drug, 26% practices and 2% consultations). Group 3 had the lowest average total 
expenditure (AR$ 925), followed by Group 4 (AR$ 1264), Group 1 (AR$ 1881) and 
Group 2 (AR$ 2133). CONCLUSIONS: Although preliminary, these results suggest 
that educational interventions improve clinical indicators and reduce direct medical 
costs associated with diabetes with a satisfactory cost-effectiveness.
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COST-EFFECTIVENESS OF SOMASTATIN ANALOGUES FOR THE 
TREATMENT OF ACROMEGALY IN COLOMBIA
Alfonso R1, Izquierdo C2, Diaz-Sotelo OD2, Maestre K3, Zarate JP3
1University of Washington, Seattle, WA, USA, 2RANDOM Foundation, Bogota, DC, 
Colombia, 3Novartis A.G., Bogotá, DC, Colombia
OBJECTIVES: To evaluate the cost-effectiveness of somatostatin analogues in the 
treatment of acromegaly in Colombia. METHODS: Cost-effectiveness of both soma-
tostatin analogues, octreotide and lanreotide, was estimated using decision analysis. 
Response to treatment in the model was derived from a recent meta-analysis. Costs 
and resource utilization included only data directly related to the treatment of the 
acromegaly during the 2 year time-horizon in Colombia. Transition probabilities were 
calculated based on the efﬁcacy results from clinical trials pooled in the meta-analysis. 
The model’s effectiveness outcome is patients who are successfully controlled in terms 
of their Growth Hormone <2.5 mcg. RESULTS: Using the estimated prevalence of the 
disease in Colombia, a hypothetical cohort of 2,503 subjects with acromegaly with 
an average age of 50 years was included in the model. The total annual medical treat-
ment costs for the octreotide group were COP$ 162,802 million, compared to the 
total annual costs for the lanreotide group of COP$ 214,047 million. In the octreotide 
arm 65.3% of the patients and in the lanreotide arm 59.5% of the patients were 
successfully controlled. The estimated number of deaths was 164 and 168 for the 
groups with octreotide and lanreotide, respectively. Because the costs are lower and 
the effectiveness is higher for octreotide in comparison with lanreotide, octreotide is 
more cost-effective (dominant). Probabilistic sensitivity analyses were consistent 
showing octreotide as the most cost-effective option. . CONCLUSIONS: Costs and 
effects of octreotide compare favorably to those of lanreotide in the treatment of 
acromegaly in Colombia. Sensitivity analysis showed that despite the uncertainty in 
cost-effectiveness ratio this result is robust.
PDB29
COST/EFFECTIVENESS STUDY OF THIAZOLIDINEDIONES IN DIABETIC 
MEDICATION∼A TAIWANESE EMPIRICAL STUDY
Huang WF1, Tsai YW1, Hsiao FY2, Hsieh CF1, Yang CL1
1Institute of Health & Welfare Policy, National Yang-Ming University, Taipei, Taiwan, 
2University of Maryland School of Pharmacy, Baltimore, MD, USA
OBJECTIVES: Using Taiwan’s National Health Insurance (NHI) claims data, we took 
thiazolidinediones (TZDs) as study target to explore its impact on medical expenditure 
and prognosis of diabetic patients. METHODS: This is a population-based retrospec-
tive cohort study on diabetic patients during 2000∼2006. Our study population was 
those who had a diagnosis of diabetes and took oral hypoglycemic agents. We classi-
A60 Abstracts
ﬁed the study population into groups by their oral hypoglycemic agents, and further 
analyzed the hazard ratio of myocardial infarction (MI) in different add-on medication 
and the survival of cardiovascular diseases between add-on TZDs group and non-TZD 
group. NMB regression model was used to estimate the cost-effectiveness difference 
on patients who used TZDs versus non-TZD users. RESULTS: The Cox proportional 
hazard model analysis demonstrated that sulfonylurea +rosiglitazone group had a 
higher risk of hospitalization for cardiovascular diseases comparing to add-on met-
formin group (HR 1.48, 95% CI: 1.21–1.80); As to the cost-effectiveness analysis: 1) 
Comparing to sulfonylurea+metformin group, the average annual medication cost 
(AAMC) per capita of sulfonylurea+rosiglitazone group increased NT$12,944, but the 
average days for hospitalization decreased 0.12 day; while the AAMC of sulfonylurea 
+pioglitazone group increased NT$10,329, but the average days for hospitalization 
decreased 0.22 day. 2) Comparing to metformin+sulfonylurea group, the AAMC of 
metformin+rosiglitazone group increased NT$11,486 dollars, but the average day for 
hospitalization decreased 0.09 day; while metformin+rosiglitazone group increased 
NT$11267, but the average days for hospitalization decreased 0.18 day. CONCLU-
SIONS: Our results demonstrated that sulfonylurea + rosiglitazone group had a higher 
risk of hospitalization for cardiovascular diseases versus metformin group with TZD 
add-on treatment (HR 1.48, 95% CI: 1.21–1.80), and per capita AAMC was higher 
(NT$12944 increment) which was not justiﬁed in the decrease of 0.12 hospitalization 
days 0.12. As for other metformin add-on groups, the increased medication cost was 
also not justiﬁed.
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COST-EFFECTIVENESS ANALYSIS OF THE DIABETES MEDICATIONS IN 
MEDICARE WITH SAS
Wang X
University of Louisville, Louisville, KY, USA
OBJECTIVES: The primary purpose of this study is to estimate the cost efﬁciency of 
the diabetes medications in Medicare in the year 2005 and the year 2006 to investigate 
the impact of Medicare, Part D. METHODS: In this study, several data sets from the 
Medical Expenditure Panel Survey are used as collected by the Agency for Healthcare 
Research and Quality. The data sets provide information on the prescribed drug, 
demography, ofﬁce-based visits, outpatients and inpatients for the years 2005 and 
2006.The analysis is based on the Medicare payments for anti-diabetic drugs, without 
considering the drug forms and cost-efﬁciency as measured by the Medicare payment 
amounts for ofﬁce-based visits, inpatients or outpatients. Statistics methods used 
include One-Way Frequencies, Summary Statistics, Box and Whisker Plots, Linear 
Multiple Regression and Spearman’s rank correlation. SAS SQL and some SAS func-
tions such as the MDY function and 0–1 indicator functions are utilized to preprocess 
the data. RESULTS: Results demonstrate that metformin users have fewer physician 
visits, lab tests and shorter length of stay in the hospital and it has a negative relation-
ship with the former two factors. Insulin, metformin and its combination with glybu-
ride are signiﬁcant to predict the frequencies of doctor ofﬁce visits, lab tests and length 
of stay. From the year 2005 to the year 2006, insulin and metformin users reduce 
their frequencies of physician visits and lab tests as well as days in the hospital. 
CONCLUSIONS: Among the diabetes medications in Medicare, metformin is the most 
cost-effective drug due to the fewest Medicare expenditures for ofﬁce-based visits, 
inpatients and outpatients with spending one dollar on the drug. In 2006, with Medi-
care part D, metformin becomes more efﬁcient, while insulin becomes more effective 
at the cost of an increased price .Therefore, it is recommended to prescribe metformin 
for the Medicare diabetic beneﬁciaries.
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REDUCED LONG-TERM COSTS AND CARDIOVASCULAR 
COMPLICATIONS IN PATIENTS INITIATED ON RAPID-ACTING INSULIN 
ASPART COMPARED WITH HUMAN INSULIN
Pollock R1, Valentine W1, Thomsen TL2, Nishimura H3
1Ossian Health Economics and Communications, Basel, Switzerland, 2Novo Nordisk A/S, 
Virum, Denmark, 3Osaka Saiseikai Nakatsu Hospital, Osaka, Kansai, Japan
OBJECTIVES: The NICE study was a ﬁve-year, open-label, randomized controlled 
trial that compared cardiovascular outcomes in Japanese type 2 diabetes patients 
intensively treated with human insulin (HI) or insulin aspart (IAsp). Using data from 
the NICE study, the cost-effectiveness of IAsp versus HI was evaluated from the 
perspective of a third-party health care payer over a ten-year time horizon (ﬁve years 
within-trial observation and ﬁve years post-trial extrapolation). METHODS: A dis-
crete event simulation model was developed in Microsoft Excel® to assess the within-
trial cost-effectiveness and make longer-term clinical projections in patients treated 
with regular human insulin or insulin aspart. Life expectancy, quality-adjusted life 
expectancy, cardiovascular event rates and costs were evaluated over a ten-year time 
horizon. Event costs were calculated from hospital receipt data supplied by the Japa-
nese Medical Data Center. Annual insulin costs were obtained from the NICE study. 
Other pharmacy costs were assumed to be the same in both treatment arms and were 
not captured in the analysis. All costs were expressed in 2008 Japanese Yen (JPY) and 
future costs and clinical beneﬁts were discounted at 3% annually. Sensitivity analyses 
were performed. RESULTS: Compared with HI, IAsp was dominant (life- and cost-
saving) over a ten-year time horizon. IAsp was associated with an improvement in 
discounted life expectancy of 0.056 years and an improvement of 0.085 quality-
adjusted life years (QALYs) versus HI. Insulin aspart was projected to save an average 
of JPY 290,719 per patient. As in the exclusively in-trial analysis, pharmacy costs were 
found to be higher (difference JPY 129,408), but were again more than offset by cost 
savings resulting from a reduced incidence of cardiovascular complications, a differ-
ence of JPY -420,126. CONCLUSIONS: In a Japanese type 2 diabetes population, 
prescribing rapid-acting insulin aspart signiﬁcantly reduced cardiovascular complica-
tions, resulting in increased quality of life and decreased costs compared with human 
insulin.
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ECONOMIC AND HEALTH CONSEQUENCES OF THE USE OF A DPP4 
PLUS METPHORMINE SCHEME IN THE TREATMENT OF PATIENTS 
WITH TYPE 2 DIABETES IN MEXICO FROM THE PRIVATE PERSPECTIVE
Anaya P1, Juarez-Garcia A2, Vargas-Valencia J3, Uc-Coyoc R2, Donato BM4, Islas S5
1AstraZeneca, Naucalpan, Mexico, 2Bristol Myers Squibb, D.F., Mexico, 3Econopharma 
Consulting, D.F., Mexico, 4Bristol-Myers Squibb Co, Wallingford, CT, USA, 5Mexican Social 
Security Institute, D.F., Mexico
OBJECTIVES: To estimate the economic and health consequences of the use of DPP4 
plus metformin in the treatment of patients with type 2 diabetes in Mexico METHODS: 
A cost-effectiveness analysis was done using a discrete event model to simulate the 
behavior of a hypothetic population with 40 years follow-up, to evaluate the number 
of complications (ischemic heart disease, myocardial infarction, congestive heart 
failure, stroke, amputation, retinopathy and ESRD), their costs and quality-adjusted 
life years (QALY’s); and the expected cost with the use of metformin+DPP4 (MDPP4), 
metformin+sulfonylureas (MSU), metformin+thiazolidinediones (MTZ) and metfor-
min (MF). The demographic and clinical background of the patients used in the model 
was obtained based on expert panel opinions (11 physicians). A systematic literature 
review was performed to get information on effectiveness (reduction in HbA1c level 
and related complications risk as reported in the UKPDS) and quality of life. Utiliza-
tion of health care resources was collected from clinical ﬁles (n = 182) at Hospital 
General Zona n° 8 of the Mexican Social Security Institute. Private costs of complica-
tion treatments were obtained from institutional sources applying a conversion ratio 
of 2.46 times as referred in the literature. Drug prices as based on private reference 
prices (ﬁxed by the regulatory authorities). All costs are expressed in 2009 US$. 
Probabilistic sensitivity analysis was performed (1000 Monte Carlo iterations) and 
acceptability curves were constructed. Both cost and QALY’s were discounted at 5% 
RESULTS: The expected treatment cost and QALY’s for MF is $250,213.26 and 
12.97 respectively; MSU $255,910.09 and 13.26; MTZ $255,177.26 and 13.27; 
MDPP4 $245,055.52 and 13.41. The probability of being cost-effective at a threshold 
of $30,621.30 (equivalent to 3 times the Mexican GDP per-capita) with MSU is 
0.543 CI95%(0.512–0.574); MTZ 0.593 CI95%(0.563–0.623); and MDPP4 
0.867 CI95%(0.846–0.888) CONCLUSIONS: The scheme based on metformin+DPP4 
presents the best cost effectiveness ratio against metformin+sulfonylureas or 
metformin+thiazolidinediones.
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ECONOMIC EVALUATION OF THREE FIRST-LINE MEDICATIONS IN 
PAINFUL DIABETIC PERIPHERAL NEUROPHATY IN MEXICO
Carlos F1, Ramirez J1, Galindo-Suarez RM2, Dueñas H2
1R A C SALUD CONSULTORES S.A. de C.V., México, D.F., Mexico, 2Eli Lilly de México,S.A. 
de C.V., Mexico City, Mexico
OBJECTIVES: Diabetic Peripheral Neuropathic Pain (DPNP) is a chronic neuropathic 
condition that signiﬁcantly affects both health-related quality of life and functional 
status, causing depression and disabilities, increased health care utilization and high 
costs. We aimed to perform an economic evaluation of three recommended ﬁrst-line 
medications for DPNP. METHODS: The analysis was conducted using a three-month 
decision model, which compares duloxetine 60mg once daily (DUL), gabapentin 
600mg 3-times daily (GAB) and pregabalin 150mg twice daily (PRE) for patients with 
DPNP and moderate to severe pain, under the perspective of public health care system 
in Mexico. Efﬁcacy rates were gathered from published literature. Adherence (based 
in number of daily doses needed) and adverse effects (AE) rates were incorporated 
into the model. Direct medical costs included drug acquisition and additional medical 
consultation due to lack of efﬁcacy (poor pain relief) or intolerable AE. Unit costs 
were taken from local public tariffs. All costs were calculated in 2009 Mexican Pesos 
(MXP) and then expressed in USD. Proportion of patients with Good Pain Relief 
(GPR) and expected quality-adjusted life years (QALY) by patient was assessed. 
RESULTS: Branded GAB and PRE were both dominated by generic GAB and DUL. 
Compared to branded GAB and PRE, DUL leads to savings of 98 and 129 USD per 
patient, respectively. The incremental cost per QALY gained with DUL used instead 
of generic GAB is 8821 USD. This amount is similar to the estimated gross domestic 
product per capita in Mexico during 2008 year. DUL was cost-effective compared to 
generic GAB in about 83% of the samples during a second-order Monte Carlo simula-
tion. CONCLUSIONS: DUL had lower costs and better health outcomes when com-
pared to both branded GAB and PRE. According to the recommendations stated by 
the World Health Organization, DUL can be seen as a cost-effective intervention 
compared to generic GAB.
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A COST-MINIMIZATION ANALYSIS FOR TYPE 2 DIABETES WITH 
INSULIN GLARGINE COMPARED TO INSULIN DETERMIR IN A BASAL 
SUPPORTED ORAL THERAPY IN CHINA
Dong H
Zhejiang University, Hanzhou, China
OBJECTIVES: To compare the treatment costs in China of 2 basal insulin analogues, 
glargine and determir, when used in combination with oral antidiabetic drugs(basal 
supported oral therapy) in insulin naïve type 2 diabetes patients. METHODS: The 
